Oncotarget

Research Papers:

Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia

Jin-long Shi, Lin Fu, Qing Ang, Guo-jing Wang, Jun Zhu and Wei-dong Wang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:2585-2595. https://doi.org/10.18632/oncotarget.6226

Metrics: PDF 1161 views  |   HTML 1550 views  |   ?  


Abstract

Jin-long Shi1,*, Lin Fu2,*, Qing Ang1, Guo-jing Wang1, Jun Zhu1 and Wei-dong Wang1

1 Medical Engineering Support Center, Chinese PLA General Hospital, Beijing, China

2 Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing, China

* These authors have contributed equally to this work

Correspondence to:

Wei-dong Wang, email:

Keywords: ATP1B1, expression, prognosis, CN-AML

Received: May 10, 2015 Accepted: October 09, 2015 Published: October 25, 2015

Abstract

ATP1B1 encodes the Na,K-ATPase β subunit, a key regulator of the Na+ and K+ electrochemical gradients across the plasma membrane and an essential regulator of cellular activity. We used several microarray datasets to test the prognostic efficacy of ATP1B1 expression in cytogenetically normal acute myeloid leukemia (CN-AML). Within the primary cohort (n = 157), high ATP1B1 expression (ATP1B1high) was associated with shorter overall survival (OS) and event-free survival (EFS) (P = 0.0068, P = 0.0039, respectively). Similar results were also obtained in the European Leukemia Net (ELN) Intermediate-I genetic category (OS: P = 0.0035, EFS: P = 0.0007). Multivariable analyses confirmed ATP1B1high is an independent predictor of shorter OS (P = 0.042) and EFS (P = 0.035). Analysis of another CN-AML cohort confirmed that ATP1B1high is associated with shorter OS (P = 0.0046, n = 162). In addition, up-regulation of oncogenes/onco-microRNAs such as MYCN, CCND2, CDK6, KIT and miR-155, among others, was associated with ATP1B1high, which may be indicative of ATP1B1’s leukemogenicity. Our results may improve risk stratification and indicate new therapeutic targets for CN-AML.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 6226